Flamel Finds New Basulin Partner, Signs $165M Bristol-Myers Deal Aug. 28, 2003 By Brady Huggett Flamel Technologies SA again has partnered its recombinant human insulin product, Basulin; this time, signing a deal with Bristol-Myers Squibb Co. valued at up to $165 million. (BioWorld Today)Read More
IPOs On The Rise: Nitromed, Pharmion, Acusphere On File Aug. 22, 2003 By Brady Huggett and Aaron Lorenzo Three biotech companies recently have filed for initial public offerings in what appears to be a developing trend. (BioWorld Today)Read More
